In:
Hepatology Research, Wiley, Vol. 39, No. 9 ( 2009-09), p. 898-909
Kurzfassung:
Aim: The cure rate of current interferon (IFN) therapy is limited to approximately 50% and most of the relapses after therapy are caused by genotype‐1. To develop a relapse model in cell culture, we attempted to obtain genome‐length hepatitis C virus ribonucleic acid (HCV RNA) harboring cells possessing the IFN‐α‐resistance phenotype from previously established OR6 cells, which enabled the luciferase reporter assay for monitoring of HCV RNA replication. Methods: The IFN‐α‐resistant HCV RNA‐harboring cells and control cells were obtained by the treatment of OR6 cells with and without IFN‐α, respectively. Then, we examined the relapse of HCV in IFN‐α‐resistant HCV RNA‐harboring cells. Results: Only type I IFN (α and β) showed significantly different anti‐HCV activity between IFN‐α‐resistant HCV RNA‐harboring cells and control cells. There was no significant difference in the anti‐HCV activity of IFN‐γ, fluvastatin, or cyclosporine A between the two types of cells. Furthermore, we showed that fluvastatin or cyclosporine A in combination with IFN‐α could prevent the relapse after therapy in the IFN‐α‐resistant HCV RNA‐harboring cells. Conclusion: We developed a HCV relapse model in cell culture using IFN‐α‐resistant HCV RNA‐harboring cells. Thus anti‐HCV reagents, which have a mechanism different from IFN‐α, were shown to be useful for preventing a relapse of IFN‐α‐resistant HCV.
Materialart:
Online-Ressource
ISSN:
1386-6346
,
1872-034X
DOI:
10.1111/hep.2009.39.issue-9
DOI:
10.1111/j.1872-034X.2009.00525.x
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2009
ZDB Id:
2006439-1
Permalink